scholarly journals Erratum

2016 ◽  
Vol 6 (4) ◽  
pp. 622-622
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Practice Patterns ◽  
International Study ◽  
Hypertension Management ◽  
Physician Survey ◽  
Clinical Practices ◽  
Discussion Section ◽  
Consensus Recommendations ◽  
Pulmonary Arterial

In “An international physician survey of pulmonary arterial hypertension management,” by Preston et al. ( Pulmonary Circulation 6:338–346), several corrections by the author were not incorporated into the final print version. The following sentence was added to the end of the second paragraph: “Furthermore, a recent survey of international PAH experts has also suggested that real-world practice patterns differ from consensus recommendations and between locations.12” In the “Discussion” section, these sentences were added after the first sentence: “Another international study of PAH experts was recently published. Like our study, the survey carried out by Ryan et al.12 identified differences between consensus recommendations and clinical practices.” A new entry (12) was added to the References: Ryan JJ, Butrous G, Maron BA. The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts. Pulm Circ 2014;4(3):441–451. The final version of the article can be found in the online edition. The publisher regrets these errors.

scholarly journals An International Physician Survey of Pulmonary Arterial Hypertension Management

2016 ◽  
Vol 6 (3) ◽  
pp. 338-346 ◽  
Author(s):  
Ioana R. Preston ◽  
Barbara Hinzmann ◽  
Sabina Heinz ◽  
Henning Gall ◽  
David Jenkins ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Hypertension Management ◽  
Physician Survey ◽  
Pulmonary Arterial

Referral centres and patient education

ESC CardioMed ◽  
2018 ◽  
pp. 2557-2558
Author(s):  
J. Simon ◽  
R. Gibbs
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Patient Education ◽  
Arterial Hypertension ◽  
Hypertension Management ◽  
High Quality ◽  
Outcome Relationship ◽  
Specialist Referral ◽  
Volume Outcome ◽  
Pulmonary Arterial

The need to engender high-quality clinical outcomes for a rare and lethal disease is best served by specialist referral centres with a high patient volume, although the volume–outcome relationship has not been shown specifically for pulmonary hypertension. The link between access to information and successful pulmonary arterial hypertension management is well established. Healthcare professionals report that patients who receive comprehensive guidance at the beginning of treatment have better outcomes. Information is understood to motivate patients to participate in their own care, thereby improving outcomes.

scholarly journals Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

2020 ◽  
Vol 10 (2) ◽  
pp. 204589402092015 ◽  
Author(s):  
John J. Ryan ◽  
Lana Melendres-Groves ◽  
Roham T. Zamanian ◽  
Ronald J. Oudiz ◽  
Murali Chakinala ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Standard Of Care ◽  
Care Practice ◽  
High Likelihood ◽  
Clinical Practices ◽  
Clinical Scenarios ◽  
Pulmonary Arterial ◽  
Pulmonary Arterial Hypertension Therapy

The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension, where pulmonary arterial hypertension-specific treatments are used. It is important to balance the ongoing care and evaluation of pulmonary arterial hypertension patients with “exposure risk” to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting pulmonary arterial hypertension therapies, for example in a patient with high-likelihood of pulmonary arterial hypertension, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when pulmonary hypertension experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiating targeted pulmonary arterial hypertension therapy in a select high-risk, high likelihood World Symposium Pulmonary Hypertension Group 1 pulmonary arterial hypertension patients. This document will highlight some of the issues facing providers, patients, and the pulmonary arterial hypertension community in real-time as the COVID-19 pandemic is evolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large.

scholarly journals Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document

2017 ◽  
Vol 7 (3) ◽  
pp. 702-711 ◽  
Author(s):  
Franck F. Rahaghi ◽  
Hassan M. Alnuaimat ◽  
Rana L.A. Awdish ◽  
Vijay P. Balasubramanian ◽  
Robert C. Bourge ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Adverse Events ◽  
Arterial Hypertension ◽  
Functional Class ◽  
Event Management ◽  
Delphi Consensus ◽  
Consensus Recommendations ◽  
Modified Delphi ◽  
Consensus Document ◽  
Pulmonary Arterial

In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug–drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.

Sign in / Sign up

Export Citation Format

Share Document